A Phase 1, Single- and Multiple-Dose Study to Assess the Safety and Pharmacokinetics of Ixekizumab (LY2439821) (Anti-IL-17 Humanized Antibody) in Chinese Patients With Psoriasis Vulgaris

Trial Profile

A Phase 1, Single- and Multiple-Dose Study to Assess the Safety and Pharmacokinetics of Ixekizumab (LY2439821) (Anti-IL-17 Humanized Antibody) in Chinese Patients With Psoriasis Vulgaris

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Ixekizumab (Primary)
  • Indications Plaque psoriasis
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 17 May 2017 Status changed from not yet recruiting to recruiting.
    • 04 Apr 2017 Planned initiation date changed from 30 Mar 2017 to 4 Apr 2017.
    • 10 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top